The American Society of Nuclear Cardiology (ASNC) has issued a new information statement urging healthcare professionals to use radiopharmaceuticals to diagnose cardiac amyloidosis in at-risk patients, amid concerns over the use of radiophosphate.
Source: prweb.comPublished on 2022-06-23
Related news
- Safety and immunogenicity of 2 - dose heterologous Ad26 . ZEBOV , MVA - BN - Filo Ebola vaccination in healthy and HIV - infected adults : A randomised , placebo - controlled Phase II clinical trial in Africa
- Local officials hope national opioid settlement will help curb crisis
- Blog : Pay - as - you - buy insurance – a customer choice - based concept
- Artificial Intelligence Is Playing a Bigger Role in Cybersecurity , But the Bad Guys May Benefit the Most
- ASNC Issues Statement on How to Use HMDP as an Alternative Radiopharmaceutical in Cardiac Amyloidosis Imaging
- Open data for smallholder weather information services
- Fiber - optic surface plasmon resonance : Key benefits